3.8 Article

A Case Report of COVID-Associated Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab

Journal

JOURNAL OF BLOOD MEDICINE
Volume 12, Issue -, Pages 929-933

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/JBM.S324873

Keywords

antiphospholipid syndrome; phospholipid autoantibodies; catastrophic APS; COVID-19; severe acute respiratory syndrome coronavirus 2; eculizumab

Categories

Ask authors/readers for more resources

Antiphospholipid syndrome (APS) and its severe manifestation Catastrophic APS (CAPS) may be affected in patients with COVID-19 infection, especially in critically ill cases. COVID-19 may exacerbate the pathological effects of APS, leading to the onset of vascular diseases.
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by multiple episodes of venous and arterial thromboses or recurrent fetal losses in the presence of antiphospholipid antibodies against beta(2)GP1, frequently accompanied by moderate thrombocytopenia. Catastrophic APS (CAPS) is a severe manifestation of APS. COVID-19 may have an intense hypercoagulable state in critically ill patients. SARS-CoV2 may potentiate pathogenic APS effects, including the activation of endothelial cells, monocytes, platelets, and complement, resulting in a proinflammatory state and prothrombotic events. The endothelial tropism of SARS-CoV2 may also modify the clinical presentation of COVID-19 in susceptible individuals and trigger flares of underlying vascular diseases. We report a case of a 64-year-old woman with a history of triple-positive APS who had multiple thrombotic and bleeding episodes after being found to have a COVID-19 infection temporally associated with CAPS development that was successfully treated with eculizumab, preventing further macro- and microvascular thrombotic events at 1 month follow-up. Our case highlights the need for more research regarding the mechanism by which COVID-19 may potentiate APS and lead to the development of CAPS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available